| Literature DB >> 36101841 |
Bartosz Kierończyk1, Mateusz Rawski2, Zuzanna Mikołajczak1, Natalia Homska2, Jan Jankowski3, Katarzyna Ognik4, Agata Józefiak5, Jan Mazurkiewicz2, Damian Józefiak1.
Abstract
The aim of this review is to present and discuss the most recent literature about the processing of insect biomass and its impact on nutritive value, further implementation of meals and fats derived from invertebrates to livestock (poultry and swine), aquaculture (salmonids), and companion animal diets and their impact on growth performance, metabolic response, and gastrointestinal microbiota shifts. Additionally, the most important barriers to obtaining unified products in terms of their nutritive value are considered, i.e., to define insects' nutrient requirements, including various technological groups and further biomass processing (slaughtering, drying, and storage). Due to the current limitation in the insect production process consisting of the lack of infrastructure, there is stress on the relatively small amount of insect products added to the animal diets as a functional feed additive. Currently, only in the case of pet nutrition may insects be considered a full replacement for commonly used environmentally harmful and allergenic products. Simultaneously, the least information has been published on this topic. Thus, more scientific data are needed, particularly when the pet food branch and insect-based diets are rapidly growing.Entities:
Keywords: Fish; Insect protein; Nutritive value; Pet; Pig; Poultry
Year: 2022 PMID: 36101841 PMCID: PMC9442335 DOI: 10.1016/j.aninu.2022.06.015
Source DB: PubMed Journal: Anim Nutr ISSN: 2405-6383
Fig. 1Frequency of the scientific articles publishing based on PubMed database using the following keywords: (A) “insect meal”, or (B) the name of species considered as livestock by the EU Commission. The bolded lines were used to emphasize the 2 most profitable insect species (Hermetia illucens and Tenebrio monitor).
The nutritive value variability of the selected insect species.1
| Item | |||
|---|---|---|---|
| Dry matter, % | 31.4 ± 5.2 | 54.0 ± 12.8 | 24.3 ± 0 |
| Crude protein, % DM | 43.3 ± 7.1 | 53.3 ± 7.4 | 54.1 ± 10.7 |
| Crude fat, % DM | 26.3 ± 11.2 | 29.8 ± 8.7 | 21.2 ± 6.3 |
| Crude ash, % DM | 12.3 ± 7.9 | 4.2 ± 1.2 | 10.2 ± 6.8 |
| Chitin, % DM | 4.6 ± 1.5 | 5.9 ± 1.4 | ND ± ND |
| AMEN for poultry, MJ/kg | 17.6 ± 3.6 | 21.7 ± 0 | 17.3 ± 0 |
| Gross Energy, MJ/kg | 24.9 ± 2.9 | 24.5 ± 2.3 | 23.1 ± 4.4 |
| Minerals, g/kg DM | |||
| Calcium | 27.2 ± 13.7 | 0.9 ± 0.7 | 9.8 ± 8.9 |
| Phosphorus | 8.9 ± 2.1 | 7.9 ± 1.5 | 10.5 ± 2.6 |
| Magnesium | 3.6 ± 1.2 | 2.2 ± 0.6 | 2.3 ± 0 |
| Potassium | 14.7 ± 5.3 | 9.1 ± 1.0 | 12.7 ± 0 |
| Sodium | 4.1 ± 3.7 | 1.2 ± 0.5 | 6 ± 0.9 |
| Chlorine | 2.0 ± 0.6 | 5.7 ± 0 | ND ± ND |
| Sulphur | 3.4 ± 1.3 | 3.5 ± 0 | ND ± ND |
| Manganese, mg/kg DM | 214.3 ± 78.5 | 11.6 ± 3.1 | 165.0 ± 154.2 |
| Zinc, mg/kg DM | 104.2 ± 32.7 | 110.8 ± 11.2 | 638.0 ± 567.1 |
| Copper, mg/kg DM | 9.4 ± 2.1 | 16.3 ± 2.9 | 33.2 ± 1.1 |
| Iron, mg/kg DM | 263.1 ± 106.5 | 70.5 ± 16.9 | 539.5 ± 91.2 |
| Cobalt, mg/kg DM | 0.3 ± 0.3 | ND ± ND | ND ± ND |
| Molybdenum, mg/kg DM | 0.9 ± 0.3 | ND ± ND | ND ± ND |
| Amino acids, g/100 g of protein | |||
| Lysine | 6.2 ± 0.9 | 4.6 ± 1.9 | 6.9 ± 1.5 |
| Threonine | 3.9 ± 0.5 | 3.6 ± 0.9 | 4.9 ± 1.3 |
| Methionine | 1.8 ± 0.4 | 1.2 ± 0.5 | 3.8 ± 1.6 |
| Cystine | 0.7 ± 0.2 | 1.4 ± 0.6 | 1.0 ± 0.3 |
| Tryptophan | 1.5 ± 0.4 | 1.2 ± 0.5 | 1.4 ± 0.2 |
| Isoleucine | 4.3 ± 0.5 | 4.0 ± 1.3 | 3.7 ± 1.3 |
| Valine | 5.9 ± 0.4 | 5.3 ± 1.9 | 4.7 ± 1.8 |
| Leucine | 6.9 ± 0.6 | 6.6 ± 2.3 | 6.1 ± 0.6 |
| Phenylalanine | 4.1 ± 0.9 | 3.4 ± 1.0 | 7.1 ± 1.5 |
| Tyrosine | 5.9 ± 1.4 | 5.9 ± 1.5 | 5.6 ± 1.8 |
| Histidine | 3.1 ± 0.8 | 2.9 ± 1.1 | 4.0 ± 1.0 |
| Arginine | 5.3 ± 1.2 | 4.5 ± 1.4 | 6.0 ± 1.6 |
| Aspartic acid | 8.9 ± 0.8 | 7.3 ± 2.2 | 8.0 ± 2.6 |
| Glutamic acid | 11.1 ± 1.2 | 10.9 ± 3.1 | 11.8 ± 3.7 |
| Glycine | 5.0 ± 0.7 | 4.8 ± 1.7 | 3.3 ± 1.6 |
| Serine | 4.1 ± 0.3 | 4.3 ± 1.6 | 3.9 ± 0.2 |
| Proline | 5.4 ± 0.5 | 5.8 ± 1.87 | 4.6 ± 0.7 |
| Alanine | 6.3 ± 0.8 | 7.1 ± 2.19 | 5.0 ± 0.7 |
AMEN = apparent metabolizable energy corrected to zero nitrogen balance; ND = not detected.
The presented values are based on the literature listed separately in Supplementary material.
Comparison of the protein dispersibility index (PDI) values of the selected feed materials.
| Item | Process | Parameters | PDI, % | Reference |
|---|---|---|---|---|
| Feed material | ||||
| Whole soybeans | – | – | 88.6 | |
| Soybeans | Roasted | 143 °C | 18.6 | |
| Raw maize-based food | – | – | 69.3 | |
| Maize-based food | Extrusion | 100 °C | 46.6 | |
| Maize-based food | Extrusion | 120 °C | 29.6 | |
| Maize-based food | Extrusion | 135 °C | 18.9 | |
| Animal byproducts | Raw | – | 7.87 to 8.28 | |
| Animal byproducts | Rendered | 141.8 °C, 23.8 min; 2.3 bars | 11.02 to 15.42 | |
| | Drying | 100 °C, 24 h | 22.60 | Authors data (unpublished) |
| | Drying | 100 °C, 24 h | 19.38 | |
| | Drying | 70 °C, 48 h | 29.05 | |
| | Freezing | −80 °C, 24 h freeze-dried | 52.86 | |
| | Microwave drying | 450 W, 20 min | 31.15 | |
| | Scalding | Boiling water 5 min; freezing at −18 °C and freeze-dried | 34.35 | |
| | Blanching | Steam 5 min; freezing at −18 °C and freeze-dried | 33.70 | |
| | Microwave drying | 900 W at 120 °C, 5 bars pressure 5 min; frozen −18 °C and freeze-dried | 42.45 | |
| | Fat extraction | n-hexane | 29.09 | |
| | Fat extraction | 2-methyloxolane | 31.55 | |
| Average PDI value of soybean by origin | ||||
| Argentina | 10.3 to 23.9 | |||
| Brasil | 8.9 to 17.6 | |||
| USA | 8.8 to 45.7 | |||
| India | 9.6 to 33.6 | |||
1 bar = 100 kPa.
Antimicrobial peptides (AMPs) from Hermetia illucens inhibited microorganisms.
| AMP name | Source/samples | Amino acid sequence | Techniques | Inhibited microorganisms | MIC | AMP gene expression | Ref. |
|---|---|---|---|---|---|---|---|
| Cecropin-like peptide 1 (CLP1) | Hemolymph of immunized | MNFTKLFVVFAVVLVAFAGQSEAGWRKRVFKPVEKFGQRVRDAGVQGIAIAQQGANVLATARGGPPQQG | Fast protein liquid chromatography (FLPC), high-performance liquid chromatography (HPLC), matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry (MS), RT–PCR | 0.52 to 1.03 μmol/L | AMP gene expression was increased in the muscle and trachea. | ||
| 1.03 to 2.07 μmol/L | |||||||
| 1.03 to 2.07 μmol/L | |||||||
| MRSA KCCM 40881 | ND | ||||||
| ND | |||||||
| ND | |||||||
| Cecropin-like peptide 2 (CLP2) | Hemolymph of immunized | MNFAKLFVVFAIVLVAFSGQSEAGWWKRVFKPVEKLGQRVRDAGIQGLEIAQQGANVLATARGGPPQQG | FLPC, HPLC, MALDI-TOF, MS, RT–PCR | – | – | ||
| MRSA | |||||||
| Cecropin-like peptide 3 (CLP3) | MNFTKLFVVFAVVLIAFSGQSEAGWWKRVFKPVERLGQRVRDAGIQGLEIAQQGANVLATVRGGPPQQG | ||||||
| CecropinZ1 | Crushed | GWLKKIGKMKFILGTTLAIVIAIFGQCQAATWSYNPNGGATVTWTANVAATAR | 3D structures of the AMP genes; protein expression, antimicrobial activity assay | 15 to 30 μg/mL | – | ||
| 54 μg/mL | |||||||
| 98 μg/mL | |||||||
| Cecropin 1 (Hicec1) | Hemolymph of | Full sequence not presented in references | Antimicrobial activities; analysis of AMPs transcripts | Range 100 to 200 μg/100 μL for all analyzed microorganism | – | ||
| Defensin-like peptid 1 (DLP1) | Hemolymph of immunized | MRSVLVLGLIVAAFAVYTSAQPYQLQYEEDGLDQAVELPIEEEQLPSQVVEQHYRAKRATCDLLSPFKVGHAACALHCIALGRRGGWCDGRAVCNCR | HPLC, concentration assessment kit BCA (Pierce) | – | – | – | |
| Defensin-like peptid 2 (DLP2) | Hemolymph of immunized | MRSILVLGLIVAAFAVYTSAQPYQLQYEEDGPGYALELPSEEEGLPSQVVEQHYRAKRATCDLLSPFKVGHAACALHCIAMGRRGGWCDGRAVCNCRR | HPLC, antimicrobial ability | 0.1 μmol/L | – | ||
| 0.12 μmol/L | |||||||
| 0.23 μmol/L | |||||||
| 0.93 μmol/L | |||||||
| 0.12 μmol/L | |||||||
| >29.97 μmol/L | |||||||
| Defensin-like peptid 3 (DLP3) | Hemolymph of immunized | MRSILVLGLIVAVFGVYTSAQPYQLQYEEDGPEYALVLPIEEEELPSQVVEQHYRAKRATCDLLSPFGVGHAACAVHCIAMGRRGGWCDDRAVCNCRR | FLPC, HPLC, MALDI-TOF, MS, RT–PCR | – | – | ||
| Defensin-like peptid 4 (DLP4) | Hemolymph of | MVHCQPFQLETEGDQQLEPVVAEVDDVVDLVAIPEHTREKRATCDLLSPFKVGHAACAAHCIARGKRGGWCDKRAVCNCRK | FLPC, HPLC, MALDI-TOF, MS, RT–PCR | MRSA clinical isolated, multidrug resistant | 0.5 to 1.17 μmol/L | ||
| 0.06 to 1.17 μmol/L | |||||||
| 1.17 to 2.34 μmol/L | |||||||
| 0.02 to 0.04 μmol/L | |||||||
| 0.59 to 1.17 μmol/L | |||||||
| not observed antimicrobial activity against Gram-negative bacteria | – | ||||||
| Defensin 1 (hidef1) | Hemolymph of | Sequence available in Antimicrobial Peptides Database (AP03308): ATCDLLSATKVKSTACAAHCLLKGHKGGYCNSKLVCVCR | Antimicrobial activities, analysis of AMPs transcription | Range 100 to 200 μg/100 μL for all analyzed microorganism | – | ||
| Immunized | MASKFLGNPNHNIGGGVFAAGNTRSNTPSLGAFGTLNLKDHSLGVSHTITPGVSDTFSQNARLNILKTPDHRVDANVFNSHTRLNNGFAFDKRGGSLDYTHRAGHGLSLGASHIPKFGTTAELTGKANLWRSPSGLSTFDLTGSASRTFGGPMAGRNNFGAGLGFSHRF | – | – | HI-attacin transcripts levels a 27.5-fold increased in the fat body, a 4-fold increase in fore-gut, a 10.2-fold increase in muscle, and a 3.7-fold increase | |||
| MRSA | |||||||
| Sarcotoxin 1, 2a, 2b, and 3 | Crushed | Sarcotoxin 1: GWLKRKIGMKFILGTTLAIVVAIFGQCQAATWSYNPNGGATVTWTANVAATAR Sarcotoxin 2a: GWLKRKIGKKFILGTTLAIVVAIFGQCQAATWSYNPNGGATVTWTANVAATAR Sarcotoxin 2b: GWLKRKIGKKFILGTTLAIAVAIFGQCQAATWSYNPNGGATVTWTANVAATAR Sarcotoxin 3: GWLKRKIGMMMKNSNFNSTEEREAAKKNYKRKYVPWFSGANVAATAR | Analysis of gene and 3D structures | – | – | ||
| StomoxynZH1 | Crushed | RGFRKHFNNLPICVEGLAGDIGSILLGVG | 3D structures of the AMP genes; protein expression, antimicrobial activity assay | 15 to 30 μg/mL | – | ||
| 27 to 54 μg/mL | |||||||
| >98 μg/mL | |||||||
| Fractioned extract of | Lyophilized | – | The water-soluble extract was applied to Sep-Pak C18, elution with 80% acetonitrile (ACN) | MRSA | 25 mg/mL | – | |
| 12.5 mg/mL | |||||||
| 50 mg/mL |
AMP = antimicrobial peptide; MIC = minimal inhibitory concentration; MRSA = methicillin-resistant Staphylococcus aureus.
Antimicrobial peptides (AMPs) from Tenebrio molitor inhibited microorganisms.
| AMP name | Source/samples | Amino acid sequence | Techniques | Inhibited microorganisms | MIC | AMP gene expression | Ref. |
|---|---|---|---|---|---|---|---|
| Tenecin 1 (homolog of sapecin) | Hemolymph immunized larvae of | Sequence available in Antimicrobial Peptides Database (AP00354): VTCDILSVEAKGVKLNDAACAAHCLFRGRSGGYCNGKRVCVCRSGGYCNGKRVCVCR | Reversed-phase (C18) open column chromatography, reversed-phase high-performance liquid chromatography (HPLC), tenecin-1 gene expression analysis | 2.0 | – | ||
| 1.0 | |||||||
| 0.8 | |||||||
| 5.0 | |||||||
| 3.7 | |||||||
| 1.6 | |||||||
| 8.0 | |||||||
| 6.0 | |||||||
| >30 | |||||||
| Tenecin 2 (coleoptericin and diptericin-like peptide) | Hemolymph | Full sequence not presented in references | Reversed-phase (C18) open column chromatography, HPLC, qRT–PCR and bactericidal activity analysis | Antimicrobial activities against | – | – | |
| Tenecin 3 | Immunized larvae of | GenBank: ( | Reversed-phase (C18) open column chromatography, HPLC; qRT–PCR; expression of MBP-tenecin 3 fusion protein in | Antifungal activity | – | Abundant transcription of tenecin-3 RNA in larvae and adults, but little in pupae; present constitutive expression in the hemolymph. | |
| Tenecin 4 | Injection of polymeric diaminopimelic acid (DAP)-type peptidoglycan (PG); immunized larvae of | GenBank ( | The antibacterial activities of AMPs with radial diffusion assays; analysis of tenecin-4 gene expression (qRT–PCR) | 0.5 | Observed changes of AMP gene expression. | ||
| 5.0 | |||||||
| No bactericidal activity against | – | ||||||
| Attacin 1a | Immunized larvae of | GenBank ( | Analysis of AMP gene expression (qRT–PCR), and antimicrobial activity | – | AMP gene expression observed in young larvae in fat body, hemocytes, and gut. | ||
| Attacin 1b | GenBank: | – | |||||
| Attacin 2 | GenBank: | – | |||||
| Coleoptericins 1 | Immunized larvae of | Full sequences not presented in references | Analysis of coleoptericins gene expression (qRT–PCR), and antimicrobial | – | AMP gene expression observed in gut, and Malpighian tubules. | ||
| Coleoptericins 2 | – | AMP gene expression observed in hemocytes, and gut; not observed in fat body of young larvae. | |||||
| Coleoptericins A | Immunized larvae of | GenBank ( | Analysis of coleoptericins gene expression (qRT–PCR) | – | – | The distribution of mRNA was highly pronounced in the gut, hemocytes, and integument tissues of late-instar larvae, and only gut and hemocytes in the adult | |
| Coleoptericins B | GenBank ( | – | – | AMP gene expression was greater during late larva, pupal day 2, pupal day 5, and adult day 1 stage, and declined in the late adult stages. | |||
| Coleoptericins C | GenBank ( | Analysis of coleoptericins gene expression (qRT–PCR) | – | – | The highest transcripts level observed in the gut, hemocytes, and the integument tissue comparing to Malpighian tubules, and fat body in late-instar larvae. | ||
| Defensin 1 | Authors indicated defensins region: MPHEDVEVFEEAVHRVERGFFCNPGLCHRQCKQSGHRRASCSGDECVCLG Defensin 1, ANTIMICROBIAL PEPTIDES DATABASE (AP02579): YPLDQVEEQDEHQVAHIRVRRVTCDLLSAEAKGVKVNHAACAAHCLLKRKRGGYCNKRRICVCRN | In silico methods, identification, and expression analyses of defensin genes; and antimicrobial activity | – | The highest AMP gene expression observed after | |||
| Defensin 2 | Full sequences not presented in references, | – | The highest expression after | ||||
| Thaumatin-like proteins 1 and 2 | Immunized larvae of | Thaumatin-like protein, GenBank (XP_012568089.2): MSDSCLMNIGGHQVTFYIHNKCPFPIWPATPSNTGQPIIAYGGFCLASSQTKKIQAPWSWSGRIWASTGCNFDSNSWKPS CETGDSDGKLACNGLIGTPP ATLDEITLQGDKGKTNFYGVSLVDGYIVPVSITPSKNINSKCNIEGCLKDVKSLCPNELQ SLESVKKKEEEEAKKKEVQL KAVKADGKSAEEVKDNGAIY | Analysis of thaumatin-like-proteins 1 and 2 gene expression (qRT–PCR) and antimicrobial activity | Antifungal activity, | – | The highest expression was observed in larvae infected with | |
| Cecropin-2 | Immunized larvae of | Antimicrobial Peptides Database (AP00135): GWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLK | In silico characterization, analysis gene expression (qRT-PCR); analysis of antimicrobial activity | – | In young larvae AMP gene expression observed in fat body, and gut; no expression observed in hemocytes, and Malpighian tubules |
AMP = antimicrobial peptide; MIC = minimal inhibitory concentration.
Effect of various invertebrate fats used as an energy source carrier on the selected poultry species organism response.
| Fat source | Species | Replaced oil | Inclusion level | Result | Reference |
|---|---|---|---|---|---|
| Broiler chickens | Soybean oil | 50%; 100% | The fatty acid profile was adversely affected. | ||
| Broiler chickens | Soybean oil | 50%; 100% | No detrimental effects. | ||
| Broiler chickens | Soybean oil | 25%; 50%; 75%; 100% | The positive impact on FCR in the first 2 weeks of age. Beneficial reduction of jejunum and ileum weight. | ||
| Broiler chickens | Soybean oil | 50%; 100% | Partial replacement induced elongation of the villi. The effect on lipase activity limitation. Acetate was reduced and butyrate enhanced in both | ||
| Broiler chickens | Soybean oil | 50%; 100% | Reduction of the gizzard relative mass. Increasing of saturated, monounsaturated fatty acids, and limitation of polyunsaturated fatty acids, and the unsaturated and saturated fatty acids ratio. | ||
| Broiler chickens | Soybean oil | 50%; 100% | The fatty acid profile was negatively enriched in saturated fatty acids. | ||
| Broiler chickens | Soybean oil | 50%; 100% | The negative microbiota shift in the birds' crop resulted from deficient releasing of lauric acid; the beneficial impact on the hindgut microecosystem. | ||
| Broiler chickens | Corn oil, coconut oil | 100% | Decreasing of feed conversion ratio (1 to 30 d) contrary to corn oil. Limitation of cholesterol and high-density lipoproteins (HDL) in the serum. Increasing the breast meat yellowness and enrich the abdominal fat in medium-chain fatty acid. | ||
| Turkeys | Soybean oil | 50%; 100% | The limitation of trypsin activity, and immune status trait concentrations (interleukin-6, tumor necrosis factor-α); the reduction of the crop digesta pH, and inhibition of Enterobacteriaceae populations in the jejunal content. Increase of total cholesterol, HDL and low-density lipoproteins (LDL) concentration in the plasma. | ||
| Laying hens | Soybean oil | 100% | No effect on the growth and laying performance, egg weight, and quality. | ||
| Broiler chickens | Palm oil, poultry fat | 100% | The positive impact on the limitation of fat, triglycerides, and total cholesterol in the liver. Improvement of fatty acid profile in the liver and breast meat. | ||
| Broiler chickens | Soybean oil | 100% | The growth performance parameters improvement till 21 d of age and digestibility through the entire rearing period or exhibit a similar effect to soybean oil. The beneficial effect on the meat quality was noticed. | ||
Effect of various invertebrate meals used as an alternative to commonly used feed materials in salmonid nutrition on their productivity and physiological traits.
| Insect species | Replaced compounds | Processing form | Species | Substitution level | Main results | Reference |
|---|---|---|---|---|---|---|
| Fishmeal | Partially defatted | Atlantic salmon ( | 33%; 66%; 100% | The effect on whole fish fatty acids composition. Increase in glucose concentration in blood plasma in the group with 66% of substitution. | ||
| Protein compounds: Fishmeal, soy protein concentrate, corn gluten, faba bean | Full-fat meal | Atlantic salmon ( | 6.25%; 12.5%; 25% | The decrease in final body weight and specific growth rate, while an increase in FCR in the 25% replacement group. A decrease in 12.5 and 25% groups in the case of crude fat and tyrosine apparent digestibility coefficient (ADC) was observed. An increase in starch digestibility in the 25% group. The lower protein efficiency ratio, apparent lipid, and energy retention in the 25% group. The decrease in lipid efficiency ratio in all groups fed with insects. | ||
| Full-fat paste | 3.7%; 6.7% | No detrimental effects. | ||||
| Fishmeal | Defatted | Rainbow trout ( | 46% | A decrease in protein efficiency ratio (PER) and protein productive value. | ||
| Fishmeal | Partially defatted | Rainbow trout ( | 10%; 20%; 30% | Modulation of gastrointestinal tract microbiota. | ||
| Fishmeal | Partially defatted | Rainbow trout ( | 25%; 50% | The decrease in ADC of dry matter and crude protein in the 50% group. Strong impact on fatty acids composition of fish fillets. | ||
| Fishmeal | Full-fat | Rainbow trout ( | 15%; 30% | The decrease in FCR values in both substitution groups. The modulation of digestive enzymes and hepatic enzymes activity. The effect on immune parameters in plasma. The impact on fatty acids composition of fish fillets. | ||
| Lower ADC of protein in 30% substitution group. Higher value of viscerosomatic index (VSI) in 30% substitution group. The modulation of digestive enzymes and hepatic enzymes activity. The effect on immune parameters in plasma. The impact on fatty acids composition of fish fillets. | ||||||
| Fishmeal | Full-fat meal | Rainbow trout ( | 30% | Impact on intestinal microbiota—lower concentration of | ||
| 41% | The decrease in villus height. Impact on intestinal microbiota—increase in concentration in all analyzed bacteria. | |||||
| 48% | A decrease in SGR and an increase in FCR. The decrease in villus height and mucosa thickness. Impact on intestinal microbiota—increase in concentration in most analyzed bacteria populations. | |||||
| 42% | Higher results of body weight gain. The increase in villus height and mucosa thickness. Impact on intestinal microbiota—increase in concentration in most analyzed bacteria. | |||||
| Fishmeal | Full-fat meal | Sea trout ( | 10% | No detrimental effects. | ||
| Hydrolyzed full-fat meal at 0.5% endopeptidase | No detrimental effects. | |||||
| Hydrolyzed full-fat meal at 1.0% endopeptidase | No detrimental effects. | |||||
| Fishmeal | Hydrolyzed full-fat meal | Sea trout ( | 42% | A decrease in PER and effect on serum biochemistry composition. The impact on the microbiota of digesta—lower concentration of | ||
| 44% | A decrease in PER. The increase in hepatosomatic index (HSI), viscerosomatic index (VSI), and liver lipid. The influence on serum biochemistry composition. The effect on the git microbiota by reducing pathogenic bacteria—lower concentration of |